(Q39654910)

13 September 2017

Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma (English)

1 reference

13 September 2017

0 references

X Zhang

1

1 reference

PubMed ID

20847752

13 September 2017

W T Godbey

series ordinal

2

1 reference

13 September 2017

17 September 2010

1 reference

13 September 2017

1 reference

13 September 2017

18

1 reference

13 September 2017

34-41

1 reference

13 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2010.50

13 September 2017

0 references

cites work

Intravesical treatments of bladder cancer: review.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Bacillus Calmette-Guerin and bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Expression-targeted gene therapy for the treatment of transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Comparison of caspase genes for the induction of apoptosis following gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Introduction of "natural" killer' cells by BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Recent advances in intravesical drug/gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Internalization of bacille Calmette-Guerin by bladder tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.50

7 January 2021

Identifiers

DOI

10.1038/CGT.2010.50

1 reference

13 September 2017

1 reference

PubMed ID

20847752